It had been reported that DR5 was significantly upregulated under such abnormal conditions as virus and tumor, which was the reason why TRAIL agonists was investigated to treat cancer (Wu et al., 1999; Koliaki and Katsilambros, 2022). This evidence concerns the gene TNFRSF10B and cancer.